Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology
- PMID: 37024522
- PMCID: PMC10079681
- DOI: 10.1038/s41523-023-00518-1
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology
Abstract
Breast cancer remains a highly prevalent disease with considerable inter- and intra-tumoral heterogeneity complicating prognostication and treatment decisions. The utilization and depth of genomic, transcriptomic and proteomic data for cancer has exploded over recent times and the addition of spatial context to this information, by understanding the correlating morphologic and spatial patterns of cells in tissue samples, has created an exciting frontier of research, histo-genomics. At the same time, deep learning (DL), a class of machine learning algorithms employing artificial neural networks, has rapidly progressed in the last decade with a confluence of technical developments - including the advent of modern graphic processing units (GPU), allowing efficient implementation of increasingly complex architectures at scale; advances in the theoretical and practical design of network architectures; and access to larger datasets for training - all leading to sweeping advances in image classification and object detection. In this review, we examine recent developments in the application of DL in breast cancer histology with particular emphasis of those producing biologic insights or novel biomarkers, spanning the extraction of genomic information to the use of stroma to predict cancer recurrence, with the aim of suggesting avenues for further advancing this exciting field.
© 2023. The Author(s).
Conflict of interest statement
Directly related to the work included in the manuscript: JSR-F reports membership of the scientific advisory board of Paige.AI and receiving personal/consultancy fees and stock options from Paige.AI. AA reports membership of the SAB and stock ownership of Trial Library. Outside the scope of the work included in the manuscript: JSR-F reports receiving consultancy fees from Goldman Sachs, REPARE Therapeutics and Personalis, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Personalis, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, AstraZeneca, Daiichi Sankyo and MSD. AA reports he is the Co-Founder of Tango, Azkarra, OviBio, Kytarro. SAB Member: Genentech, GLAdiator, Cura, Circle, Bluestar, Earli, GSK, Ambagon, PhoenixMD, Yingli, ProLynx. Board Member: Cambridge Science Corp., Cytomx. Grant/Research support from: SPARC, AstraZeneca. He holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefitted financially (and may do so in the future).
Figures



Similar articles
-
Deep computational pathology in breast cancer.Semin Cancer Biol. 2021 Jul;72:226-237. doi: 10.1016/j.semcancer.2020.08.006. Epub 2020 Aug 17. Semin Cancer Biol. 2021. PMID: 32818626 Review.
-
Data Integration Using Advances in Machine Learning in Drug Discovery and Molecular Biology.Methods Mol Biol. 2021;2190:167-184. doi: 10.1007/978-1-0716-0826-5_7. Methods Mol Biol. 2021. PMID: 32804365 Review.
-
Semi-supervised training of deep convolutional neural networks with heterogeneous data and few local annotations: An experiment on prostate histopathology image classification.Med Image Anal. 2021 Oct;73:102165. doi: 10.1016/j.media.2021.102165. Epub 2021 Jul 14. Med Image Anal. 2021. PMID: 34303169
-
Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery.Curr Med Chem. 2021;28(32):6512-6531. doi: 10.2174/0929867328666210208111821. Curr Med Chem. 2021. PMID: 33557728 Review.
-
Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development.Int J Mol Sci. 2023 Jan 19;24(3):2026. doi: 10.3390/ijms24032026. Int J Mol Sci. 2023. PMID: 36768346 Free PMC article. Review.
Cited by
-
Deep learning-based image analysis in muscle histopathology using photo-realistic synthetic data.Commun Med (Lond). 2025 Mar 6;5(1):64. doi: 10.1038/s43856-025-00777-y. Commun Med (Lond). 2025. PMID: 40050400 Free PMC article.
-
SGA-Driven feature selection and random forest classification for enhanced breast cancer diagnosis: A comparative study.Sci Rep. 2025 Mar 30;15(1):10944. doi: 10.1038/s41598-025-95786-1. Sci Rep. 2025. PMID: 40159513 Free PMC article.
-
Developing the novel diagnostic model and potential drugs by integrating bioinformatics and machine learning for aldosterone-producing adenomas.Front Mol Biosci. 2024 Jan 4;10:1308754. doi: 10.3389/fmolb.2023.1308754. eCollection 2023. Front Mol Biosci. 2024. PMID: 38239411 Free PMC article.
-
Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment.Cancers (Basel). 2023 Jul 3;15(13):3474. doi: 10.3390/cancers15133474. Cancers (Basel). 2023. PMID: 37444584 Free PMC article. Review.
-
Aligning knowledge concepts to whole slide images for precise histopathology image analysis.NPJ Digit Med. 2024 Dec 30;7(1):383. doi: 10.1038/s41746-024-01411-2. NPJ Digit Med. 2024. PMID: 39738468 Free PMC article.
References
-
- Barsoum I, Tawedrous E, Faragalla H, Yousef GM. Histo-genomics: digital pathology at the forefront of precision medicine. Acta Radiol. Diagn. 2019;6:203–212. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources